| Rasagiline |
20160015 |
Sagilia, Tablet, 1, mg, Pack: 30 |
Medochemie Ltd., Кипър |
Medochemie Ltd., Factory AZ, Limassol, Кипър |
77.26 |
15.45 |
92.71 |
4% |
3.09 |
80.35 |
16.07 |
96.42 |
16% |
12.36 |
92.71 |
18.54 |
111.25 |
|
НСР-8539/24.03.2016 и НСР-8660/01.04.2016 (допуска предварително изпълнение); КП-20/11.04.2017 и НСР-11215/15.12.2016; НСР-14042/02.10.2017 |
02.05.2017 |
02.11.2017 |
Заличен |
4214 |
| Rasagiline |
20160015 |
Sagilia, Tablet, 1, mg, Pack: 30 |
Medochemie Ltd., Кипър |
Medochemie Ltd., Factory AZ, Limassol, Кипър |
77.26 |
15.45 |
92.71 |
4% |
3.09 |
80.35 |
16.07 |
96.42 |
16% |
12.36 |
92.71 |
18.54 |
111.25 |
|
НСР-8539/24.03.2016 и НСР-8660/01.04.2016 (допуска предварително изпълнение); КП-20/11.04.2017 и НСР-11215/15.12.2016 |
02.05.2017 |
02.05.2017 |
Неактивен |
4214 |
| Rasagiline |
20160015 |
Sagilia, Tablet, 1, mg, Pack: 30 |
Medochemie Ltd., Кипър |
Medochemie Ltd., Factory AZ, Limassol, Кипър |
122.45 |
24.49 |
146.94 |
4% |
4.9 |
127.35 |
25.47 |
152.82 |
16% |
19.59 |
146.94 |
29.39 |
176.33 |
|
НСР-8539/24.03.2016 и НСР-8660/01.04.2016 (допуска предварително изпълнение) |
02.04.2016 |
02.04.2016 |
Неактивен |
4214 |
| Sulfasalazine |
II-4492/18.03.2009 |
SALAZOPYRIN EN, Gastro resistant tablet, 500, mg, Pack: 100 |
Pfizer Enterprises SARL, Люксембург |
Kemwell AB - Sweden |
9.31 |
1.86 |
11.17 |
7% |
0.65 |
9.96 |
1.99 |
11.95 |
20% |
1.86 |
11.82 |
2.36 |
14.18 |
Цената се заличава с решение НСР-3790/16.06.2014 ( в сила от 16.07.2014) |
КЦРР-2203/06.02.2013 |
03.03.2013 |
03.03.2013 |
Заличен |
1652 |
| Sulfasalazine |
II-4492/18.03.2009 |
SALAZOPYRIN EN, Gastro resistant tablet, 500, mg, Pack: 100 |
Pfizer Enterprises SARL, Люксембург |
Kemwell AB - Sweden |
13.2 |
2.64 |
15.84 |
6% |
0.79 |
13.99 |
2.8 |
16.79 |
18% |
2.38 |
16.37 |
3.27 |
19.64 |
|
КЦ-826/15.04.2009 |
30.04.2009 |
30.04.2009 |
Неактивен |
1652 |
| Salbutamol |
20030690 |
SALBUTAMOL INHALER, Pressurised inhalation, suspension, 100 mcg/metered actuation - 200 doses, mg, Pack: 1 |
GlaxoSmithKline (Ireland) Limited, Ирландия |
Glaxo Wellcome Production, France; GlaxoSmith Kline Pharmaceuticals S.A. Poland; Glaxo Wellcome S.A., Spain |
2.8 |
0.56 |
3.36 |
7% |
0.2 |
3 |
0.6 |
3.6 |
20% |
0.56 |
3.56 |
0.71 |
4.27 |
Промяна на обстоятелства НСР-18242/22.03.2019 |
НСР-2429/21.01.2014; НСР-12563/05.05.2017; НСР-15953/22.06.2018 |
07.07.2018 |
02.05.2019 |
Активен |
2452 |
| Salbutamol |
20030690 |
SALBUTAMOL INHALER, Pressurised inhalation, suspension, 100 mcg/metered actuation - 200 doses, mg, Pack: 1 |
Glaxo Group Ltd., Обединено Кралство |
Glaxo Wellcome Production, France; GlaxoSmith Kline Pharmaceuticals S.A. Poland; Glaxo Wellcome S.A., Spain |
2.8 |
0.56 |
3.36 |
7% |
0.2 |
3 |
0.6 |
3.6 |
20% |
0.56 |
3.56 |
0.71 |
4.27 |
|
НСР-2429/21.01.2014; НСР-12563/05.05.2017; НСР-15953/22.06.2018 |
07.07.2018 |
02.08.2018 |
Неактивен |
2452 |
| Salbutamol |
20030690 |
SALBUTAMOL INHALER, Pressurised inhalation, suspension, 100 mcg/metered actuation - 200 doses, mg, Pack: 1 |
Glaxo Group Ltd., Обединено Кралство |
Glaxo Wellcome Production, France; GlaxoSmith Kline Pharmaceuticals S.A. Poland; Glaxo Wellcome S.A., Spain |
2.99 |
0.6 |
3.59 |
7% |
0.21 |
3.2 |
0.64 |
3.84 |
20% |
0.6 |
3.8 |
0.76 |
4.56 |
|
НСР-2429/21.01.2014; НСР-12563/05.05.2017 |
20.05.2017 |
02.06.2017 |
Неактивен |
2452 |
| Salbutamol |
20030690 |
SALBUTAMOL INHALER, Pressurised inhalation, suspension, 100 mcg/metered actuation - 200 doses, mg, Pack: 1 |
Glaxo Group Ltd., Обединено Кралство |
Glaxo Wellcome Production, France; GlaxoSmith Kline Pharmaceuticals S.A. Poland; Glaxo Wellcome S.A., Spain |
3.13 |
0.63 |
3.76 |
7% |
0.22 |
3.35 |
0.67 |
4.02 |
20% |
0.63 |
3.98 |
0.8 |
4.78 |
|
НСР-2429/21.01.2014 |
05.02.2014 |
05.02.2014 |
Неактивен |
2452 |
| Salbutamol |
20030690 |
SALBUTAMOL INHALER, Pressurised inhalation, suspension, 100 mcg/metered actuation - 200 doses, mg, Pack: 1 |
Glaxo Group Ltd., Обединено Кралство |
Glaxo Wellcome Production, France; GlaxoSmith Kline Pharmaceuticals S.A. Poland; Glaxo Wellcome S.A., Spain |
3.72 |
0.74 |
4.46 |
7% |
0.26 |
3.98 |
0.8 |
4.78 |
20% |
0.74 |
4.72 |
0.94 |
5.66 |
|
КЦРР-2665/20.03.2013 |
19.04.2013 |
19.04.2013 |
Неактивен |
2452 |
| Salbutamol |
II-6771/12.02.2010 |
SALBUTAMOL INHALER, Pressurised inhalation, suspension, 100 mcg/metered actuation - 200 doses, mg, Pack: 1 |
Glaxo Group Ltd., Обединено Кралство |
Glaxo Wellcome Production, France; GlaxoSmithKline Pharmaceuticals SA, Poland; Glaxo Wellcome S.A., Spain |
3.89 |
0.78 |
4.67 |
7% |
0.27 |
4.16 |
0.83 |
4.99 |
20% |
0.78 |
4.94 |
0.99 |
5.93 |
|
КЦ-1683/25.06.2010 |
15.07.2010 |
15.07.2010 |
Неактивен |
2452 |
| Salbutamol |
20110698 |
Salbutamol Sandoz, Pressurised inhalation, suspension, 100 mcg/dose - 200 doses, mg, Pack: 1 |
Sandoz d.d., Словения |
Aeropharm GmbH, Francois – Mitterrand-Allee 1, 07407 Rudolstadt, Германия |
2.89 |
0.58 |
3.47 |
7% |
0.2 |
3.09 |
0.62 |
3.71 |
20% |
0.58 |
3.67 |
0.73 |
4.4 |
|
НСР-1636/11.11.2013; НСР-11770/17.02.2017; НСР-18772/21.05.2019; НСР-20729/30.01.2020 |
05.06.2019 |
02.03.2020 |
Заличен |
2246 |
| Salbutamol |
20110698 |
Salbutamol Sandoz, Pressurised inhalation, suspension, 100 mcg/dose - 200 doses, mg, Pack: 1 |
Sandoz d.d., Словения |
Aeropharm GmbH, Francois – Mitterrand-Allee 1, 07407 Rudolstadt, Германия |
2.89 |
0.58 |
3.47 |
7% |
0.2 |
3.09 |
0.62 |
3.71 |
20% |
0.58 |
3.67 |
0.73 |
4.4 |
|
НСР-1636/11.11.2013; НСР-11770/17.02.2017; НСР-18772/21.05.2019 |
05.06.2019 |
02.07.2019 |
Неактивен |
2246 |
| Salbutamol |
20110698 |
Salbutamol Sandoz, Pressurised inhalation, suspension, 100 mcg/dose - 200 doses, mg, Pack: 1 |
Sandoz d.d., Словения |
Aeropharm GmbH, Francois – Mitterrand-Allee 1, 07407 Rudolstadt, Германия |
2.97 |
0.59 |
3.56 |
7% |
0.21 |
3.18 |
0.64 |
3.82 |
20% |
0.59 |
3.77 |
0.75 |
4.52 |
|
НСР-1636/11.11.2013; НСР-11770/17.02.2017 |
04.03.2017 |
02.04.2017 |
Неактивен |
2246 |
| Salbutamol |
20110698 |
Salbutamol Sandoz, Pressurised inhalation, suspension, 100 mcg/dose - 200 doses, mg, Pack: 1 |
Sandoz d.d., Словения |
Aeropharm GmbH, Francois – Mitterrand-Allee 1, 07407 Rudolstadt, Германия |
3.19 |
0.64 |
3.83 |
7% |
0.22 |
3.41 |
0.68 |
4.09 |
20% |
0.64 |
4.05 |
0.81 |
4.86 |
|
НСР-1636/11.11.2013 |
26.11.2013 |
26.11.2013 |
Неактивен |
2246 |
| Salmeterol, Fluticasone |
20170120 |
Salmeterol and fluticasone Cipla, Pressurised inhalation, suspension, 25 mcg/250 mcg, -, Pack: 120 doses |
Cipla Europe NV, Белгия |
S&D Pharma CZ, spol. s r.o, Чешка Република; Cipla (EU) Ltd, Обединено Кралство; Cipla Europe NV, Белгия |
35.2 |
7.04 |
42.24 |
4% |
1.41 |
36.61 |
7.32 |
43.93 |
16% |
5.63 |
42.24 |
8.45 |
50.69 |
Промяна на обстоятелства НСР-19751/04.09.2019 |
НСР-15801/08.06.2018; корекционно решение НСР-16098/05.07.2018; Прот. № 280/30.05.2018 |
12.09.2018 |
02.10.2019 |
Активен |
16271 |
| Salmeterol, Fluticasone |
20170120 |
Salmeterol and fluticasone Cipla, Pressurised inhalation, suspension, 25 mcg/250 mcg, -, Pack: 120 doses |
Cipla (UK) Ltd., Обединено Кралство |
S&D Pharma CZ, spol. s r.o, Чешка Република; Cipla (EU) Ltd, Обединено Кралство; Cipla Europe NV, Белгия |
35.2 |
7.04 |
42.24 |
4% |
1.41 |
36.61 |
7.32 |
43.93 |
16% |
5.63 |
42.24 |
8.45 |
50.69 |
|
НСР-15801/08.06.2018; корекционно решение НСР-16098/05.07.2018; Прот. № 280/30.05.2018 |
12.09.2018 |
02.10.2018 |
Неактивен |
16271 |
| Salmeterol, Fluticasone |
20170119 |
Salmeterol and fluticasone Cipla, Pressurised inhalation, suspension, 25 mcg/125 mcg, -, Pack: 120 doses |
Cipla Europe NV, Белгия |
S&D Pharma CZ, spol. s r.o, Чешка Република; Cipla (EU) Ltd, Обединено Кралство; Cipla Europe NV, Белгия |
27.83 |
5.57 |
33.4 |
6% |
1.67 |
29.5 |
5.9 |
35.4 |
18% |
5.01 |
34.51 |
6.9 |
41.41 |
Промяна на обстоятелства НСР-19751/04.09.2019 |
НСР-15801/08.06.2018; корекционно решение НСР-16098/05.07.2018; Прот. № 280/30.05.2018 |
12.09.2018 |
02.10.2019 |
Активен |
16272 |
| Salmeterol, Fluticasone |
20170119 |
Salmeterol and fluticasone Cipla, Pressurised inhalation, suspension, 25 mcg/125 mcg, -, Pack: 120 doses |
Cipla (UK) Ltd., Обединено Кралство |
S&D Pharma CZ, spol. s r.o, Чешка Република; Cipla (EU) Ltd, Обединено Кралство; Cipla Europe NV, Белгия |
27.83 |
5.57 |
33.4 |
6% |
1.67 |
29.5 |
5.9 |
35.4 |
18% |
5.01 |
34.51 |
6.9 |
41.41 |
|
НСР-15801/08.06.2018; корекционно решение НСР-16098/05.07.2018; Прот. № 280/30.05.2018 |
12.09.2018 |
02.10.2018 |
Неактивен |
16272 |
| Mesalazine |
20130429 |
Salofalk, Gastro-resistant prolonged-release granules, 3000, mg, Pack: 30 |
Dr. Falk Pharma GmbH, Германия |
Dr. Falk Pharma GmbH, Германия |
95.09 |
19.02 |
114.11 |
4% |
3.8 |
98.89 |
19.78 |
118.67 |
16% |
15.21 |
114.1 |
22.82 |
136.92 |
|
НСР-12135/27.03.2017 |
11.04.2017 |
02.05.2017 |
Активен |
15637 |
| Mesalazine |
20130427 |
Salofalk, Gastro-resistant prolonged-release granules, 1000, mg, Pack: 100 |
Dr. Falk Pharma GmbH, Германия |
Dr. Falk Pharma GmbH, Германия |
111.21 |
22.24 |
133.45 |
4% |
4.45 |
115.66 |
23.13 |
138.79 |
16% |
17.79 |
133.45 |
26.69 |
160.14 |
|
НСР-5936/01.04.2015. |
16.04.2015 |
16.04.2015 |
Неактивен |
3760 |
| Mesalazine |
9600070 |
SALOFALK, Rectal suspension, 4 g/60 ml, -, Pack: 7 |
Dr. Falk Pharma GmbH, Германия |
Dr Falk Pharma GmbH, Германия |
46.94 |
9.39 |
56.33 |
4% |
1.88 |
48.82 |
9.76 |
58.58 |
16% |
7.51 |
56.33 |
11.27 |
67.6 |
|
НСР-6380/03.06.2015.; НСР-20816/13.02.2020 |
28.02.2020 |
02.03.2020 |
Активен |
2748 |
| Mesalazine |
9600070 |
SALOFALK, Rectal suspension, 4 g/60 ml, -, Pack: 7 |
Dr. Falk Pharma GmbH, Германия |
Dr Falk Pharma GmbH, Germany |
48.15 |
9.63 |
57.78 |
4% |
1.93 |
50.08 |
10.02 |
60.1 |
16% |
7.7 |
57.78 |
11.56 |
69.34 |
|
НСР-6380/03.06.2015. |
18.06.2015 |
18.06.2015 |
Неактивен |
2748 |
| Mesalazine |
9600070 |
SALOFALK, Rectal suspension, 4000, mg, Pack: 7 |
Dr. Falk Pharma GmbH, Германия |
Dr Falk Pharma GmbH, Germany |
49.58 |
9.92 |
59.5 |
4% |
1.98 |
51.56 |
10.31 |
61.87 |
16% |
7.93 |
59.49 |
11.9 |
71.39 |
|
НСР-3254/14.04.2014 |
29.04.2014 |
29.04.2014 |
Неактивен |
2748 |
| Mesalazine |
II-0544/05.09.2007 |
SALOFALK, Rectal suspension, 4000, mg, Pack: 7 |
Dr. Falk Pharma GmbH, Германия |
Dr Falk Pharma GmbH, Germany |
50.05 |
10.01 |
60.06 |
4% |
2 |
52.05 |
10.41 |
62.46 |
16% |
8.01 |
60.06 |
12.01 |
72.07 |
|
КЦРР-1054/26.07.2012 |
10.08.2012 |
10.08.2012 |
Неактивен |
2748 |